Delta Investment Management LLC Boosts Holdings in Elevance Health, Inc. $ELV

Delta Investment Management LLC increased its stake in Elevance Health, Inc. (NYSE:ELV) by 21.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,692 shares of the company’s stock after purchasing an additional 5,080 shares during the quarter. Elevance Health makes up approximately 1.7% of Delta Investment Management LLC’s portfolio, making the stock its 13th biggest holding. Delta Investment Management LLC’s holdings in Elevance Health were worth $10,058,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ELV. Artisan Partners Limited Partnership raised its position in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC raised its holdings in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after acquiring an additional 798,457 shares during the period. Brave Warrior Advisors LLC lifted its position in shares of Elevance Health by 65.3% during the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after acquiring an additional 724,349 shares in the last quarter. Baupost Group LLC MA boosted its holdings in shares of Elevance Health by 114.1% in the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock worth $426,195,000 after acquiring an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC grew its position in shares of Elevance Health by 44.2% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock valued at $660,935,000 after purchasing an additional 627,038 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of NYSE:ELV traded down $3.57 during midday trading on Thursday, hitting $373.06. The company had a trading volume of 127,081 shares, compared to its average volume of 1,869,413. The company has a market cap of $81.01 billion, a price-to-earnings ratio of 15.83, a PEG ratio of 2.13 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a fifty day moving average of $310.12 and a two-hundred day moving average of $331.59. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $424.24.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.During the same quarter in the previous year, the company posted $11.97 earnings per share. Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.8%. Elevance Health’s payout ratio is presently 29.26%.

Analyst Ratings Changes

Several research analysts have commented on ELV shares. JPMorgan Chase & Co. raised their target price on Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research note on Tuesday. Citigroup raised shares of Elevance Health to a “buy” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft upped their price target on shares of Elevance Health from $332.00 to $363.00 and gave the stock a “hold” rating in a report on Thursday, April 23rd. Robert W. Baird lifted their price objective on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Finally, Weiss Ratings upgraded Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Thirteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $384.58.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.